Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/all.14780 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Systematic review of omalizumab for refractory clonal and non-clonal mast cell activation syndrome.
Allergy Asthma Proc
January 2025
From the Section of Allergy, Asthma and Immunology, Medicine and Pediatrics, Pennsylvania State University School of Medicine, Hershey, Pennsylvania and.
Patients with mast cell activation syndrome (MCAS) can be refractory to standard antimediator therapy. Alternative treatment options to reduce disease burden and improve quality of life are needed. To compile the evidence that supports the use of omalizumab for patients with refractory MCAS.
View Article and Find Full Text PDFDo No Harm: An Ethical Approach to Refractory Anaphylaxis to Chemotherapy.
Ann Allergy Asthma Immunol
November 2024
Section of Allergy and Immunology, Division of Pulmonary, Allergy, and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. Electronic address:
Risk Factors for Refractory Anaphylaxis in the Emergency Department.
Emerg Med Int
November 2024
Department of Emergency Medicine, Ankara Etlik City Hospital, Ankara, Türkiye.
Article Synopsis
- Anaphylaxis is a life-threatening allergic reaction, and understanding its triggers is crucial for preventing severe cases known as refractory anaphylaxis (RA).
- A study analyzed data from 1,378 patients diagnosed with anaphylaxis, finding that 3.3% had RA, with a history of anaphylaxis being the strongest risk factor.
- Other factors such as the use of beta-blockers/ACE inhibitors, exposure to IV contrast agents, and symptoms of low blood pressure were also linked to increased severity, highlighting the need for prompt treatment to improve patient outcomes.
The indications and safety of rituximab for the treatment of pediatric autoimmune diseases: a single-center retrospective study.
Transl Pediatr
October 2024
Department of Pediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Background: Autoimmune diseases in children pose therapeutic challenges due to their refractory nature and the associated morbidity. Rituximab (RTX), a monoclonal antibody targeting CD20, has emerged as a promising steroid-sparing therapy for various autoimmune disorders by depleting B cells. However, its indications and safety in pediatric populations in our region remain insufficiently studied.
View Article and Find Full Text PDFCase Report: Multidisciplinary management of a patient with indolent systemic mastocytosis and refractory symptoms.
Front Allergy
October 2024
Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.
Systemic mastocytosis (SM) is a rare hematologic condition characterized by the proliferation and accumulation in tissue of clonal mast cells in multiple organ systems. The release of mast cell mediators in the indolent disease type and the predominant mast cell infiltration of tissues in advanced disease contribute to the heterogeneous clinical presentation. The disease driver in >90% of adult cases is an activating mutation, with D816V being the most frequent.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!